A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Kim, Seok-Yeon | - |
dc.contributor.author | Choi, Kee-Joon | - |
dc.contributor.author | Yoo, Byung-Su | - |
dc.contributor.author | Cha, Dong-Hun | - |
dc.contributor.author | Jung, Hae Ok | - |
dc.contributor.author | Ryu, Dong-Ryeol | - |
dc.contributor.author | Choi, Joon Hyouk | - |
dc.contributor.author | Lee, Kwang Je | - |
dc.contributor.author | Park, Tae Ho | - |
dc.contributor.author | Oh, Ju Hyeon | - |
dc.contributor.author | Kim, Sang Min | - |
dc.contributor.author | Choi, Ji-Yong | - |
dc.contributor.author | Kim, Kye Hun | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Kim, Woo-Shik | - |
dc.contributor.author | Choi, Si -Wan | - |
dc.contributor.author | Park, Dae-Gyun | - |
dc.contributor.author | Song, Pil-Sang | - |
dc.contributor.author | Hong, Taek-Jong | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Park, Seung Woo | - |
dc.date.accessioned | 2021-09-02T22:46:07Z | - |
dc.date.available | 2021-09-02T22:46:07Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81431 | - |
dc.description.abstract | Purpose: The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100 mg once daily, patients who met both blood pressure criteria (80 mm Hg <= SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100 mg + rosuvastatin 20 mg treatment (L/R 100/20) group, amlodipine camsylate 5 mg + losartan potassium 100 mg treatment (A/L 5/100) group, and amlodipine S mg + losartan potassium 100 mg + rosuvastatin 20 mg (A/L/R 5/100/20) group. The primary efficacy variables were the percent change in LDL-C in the A/L/R 5/100/20 and A/L 5/100 groups and the mean change of SiDBP in the A/L/R 5/100/20 and L/R 100/20 groups after 8 weeks of treatment, relative to baseline values. Findings: A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups. After 8 weeks of treatment, the mean (SD) percent change in LDL-C was significantly greater in the A/L/R group than in the A/L group (-48.40% [2.77%] vs -6.70% [3.00%]; P < 0.0001). Moreover, the mean change in SiDBP was significantly greater in the A/L/R group than in the L/R group (-9.75 [0.92] mm Hg vs -1.73 [1.03] mm Hg; P < 0.0001). SiDBP and LDL-C reductions in the A/L/R group were comparable to reductions in the A/L and L/R groups, respectively. Ten adverse events were reported in 7 patients (4.83%), and 1 patient from the A/L group (0.69%) experienced 2 adverse drug reactions (tachycardia and face edema), which were mild and resolved without specific treatment. There were no clinically significant tolerability issues during the treatment period. Implications: Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single pill triple combination. (C) 2017 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | SINGLE-PILL AMLODIPINE/ATORVASTATIN | - |
dc.subject | FIXED-DOSE COMBINATION | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | NATIONAL-HEALTH | - |
dc.subject | PHASE-II | - |
dc.subject | AMLODIPINE | - |
dc.subject | CHOLESTEROL | - |
dc.subject | METAANALYSIS | - |
dc.subject | VALSARTAN | - |
dc.title | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shim, Jaemin | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1016/j.clinthera.2017.10.013 | - |
dc.identifier.scopusid | 2-s2.0-85035090933 | - |
dc.identifier.wosid | 000419932000005 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.39, no.12, pp.2366 - 2379 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 39 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2366 | - |
dc.citation.endPage | 2379 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SINGLE-PILL AMLODIPINE/ATORVASTATIN | - |
dc.subject.keywordPlus | FIXED-DOSE COMBINATION | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | NATIONAL-HEALTH | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | AMLODIPINE | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | VALSARTAN | - |
dc.subject.keywordAuthor | angiotensin receptor blocker | - |
dc.subject.keywordAuthor | calcium channel blocker | - |
dc.subject.keywordAuthor | HMG-CoA reductase inhibitor | - |
dc.subject.keywordAuthor | hypercholesterolemia | - |
dc.subject.keywordAuthor | hypertension | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.